In a Los Angeles Times op-ed titled "Overhyped Alzheimer’s treatments betrayed patients’ hopes. Here’s how science should change," Jason Karlawish (PARC Research Associate) calls on scientists to consider the consequences for patients and their own personal motivations when pushing for accelerated FDA approval of new drugs and medical treatments. 

 

Citation: